Analysts Offer Predictions for YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Cantor Fitzgerald issued their FY2025 earnings estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($0.67) per share for the year. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period last year, the company posted ($0.18) earnings per share.

A number of other research firms have also issued reports on YMAB. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Stock Performance

YMAB stock opened at $6.19 on Wednesday. The firm has a market cap of $277.25 million, a P/E ratio of -11.46 and a beta of 0.69. Y-mAbs Therapeutics has a 1 year low of $6.01 and a 1 year high of $20.90. The stock has a 50-day simple moving average of $8.96 and a 200-day simple moving average of $11.82.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. State Street Corp grew its position in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after buying an additional 405,169 shares during the last quarter. Caligan Partners LP grew its holdings in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.